on Galimedix, Inc.
Galimedix Therapeutics Assembles Scientific Advisory Board for Phase 2 Study of GAL-101
Galimedix Therapeutics, Inc. has announced the formation of a Scientific Advisory Board (SAB) composed of retina experts from both clinical practice and academia. This move comes as the company prepares to initiate Phase 2 clinical trials for its lead compound, GAL-101, aimed at treating dry age-related macular degeneration (AMD).
The SAB includes notable figures from the ophthalmology sector, such as Dr. Konstantinos Balaskas (UCL Institute of Ophthalmology, UK), Dr. Justis P. Ehlers (Cole Eye Institute, USA), and others. Their expertise will guide the development of GAL-101 eye drops, which have shown promise in preclinical and Phase 1 studies.
The advisory board convened at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting to discuss the design and endpoints of the Phase 2 DREAM trial, expected to start in late 2024.
R. E.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Galimedix, Inc. news